To test whether hyperglycemia contributed substantially to the βEedKO phenotype, we used subcutaneous insulin implants to normalize blood glucose long term in βEedKO mice, initiating treatment at moderate (∼18 weeks of age; normal fasting glucose) or late-stage pathology (∼25 weeks; >90% dedifferentiation). The gene discussed is INS; the disease is Hyperglycemia.